SLC5A2 and hydrops fetalis: By incorporating studies such as the AMPLITUDE-O [9], FLOW [10], and DAPA-HF [15] trials, this review provides a detailed and contemporary comparison of SGLT2 inhibitors and GLP-1 RAs, highlighting their distinct strengths and complementary roles in cardiovascular and renal protection.